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under the CC BY-NC-SA license (http:/Summary Objectives: To examine the safety and efficacy of ombitasvir and ABT-450 with
ritonavir (ABT-450/r)  ribavirin (RBV) in treatment-na€ıve, non-cirrhotic adults with chronic
HCV genotype 1e3 infection.
Methods: Patients in this open-label, exploratory, phase 2, multicenter study received ombi-
tasvir (25 mg QD) and ABT-450/r (200/100 mg QD)  RBV for 12 weeks. Primary efficacy
endpoint was HCV RNA < lower limit of quantitation (LLOQ) from week 4 through 12. Sustained
virologic response 12 weeks post-treatment (SVR12) was a secondary endpoint.
Results: Sixty-one patients were enrolled. Among genotype 1-, 2-, and 3-infected patients,
respectively, HCV RNA was<LLOQ from week 4 through 12 in 10 (100%; 95% CI 69e100), 9
(90%; 56e100), and 7 (70%; 35e93) receiving the RBV-containing regimen and 9 (90%; 56
e100), 8 (80%; 44e97), and 2 (18%; 2e52) receiving the RBV-free regimen. Among genotype
1-, 2-, and 3-infected patients, respectively, SVR12 was achieved by 10 (100%), 8 (80%), and
5 (50%) receiving the RBV-containing regimen, and 6 (60%), 6 (60%), and 1 (9%) receiving the0 253 3426; fax: þ1 210 477 1808.
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198 E. Lawitz et al.RBV-free regimen. The most common adverse events were fatigue, nausea, and headache. One
patient discontinued due to an adverse event.
Conclusions: In this study, ombitasvir and ABT-450/r  RBV regimens were generally well-
tolerated. Sustained virologic response was achieved in most patients with HCV genotype 1
or 2 infection, but low SVR rates were observed in HCV genotype 3-infected patients.
ª 2014 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).genotypes 1, 2, and 3 in vitro. Phase 2 and 3 studies haveIntroduction
It is estimated that 150 million people worldwide have
chronic hepatitis C virus (HCV) infection.1 HCV-related
cirrhosis is a leading indication for liver transplantation
and a contributor to the increasing incidence of hepatocellu-
lar carcinoma.2 HCV is currently classified into 7 different
genotypes.3 HCV genotypes 1, 2, and 3 have a wide global
distribution.4 HCV genotype 1 is the most common world-
wide with subgenotype varying by geographic region. Subge-
notype 1a predominates in North America and some
countries in Western Europe, while subgenotype 1b predom-
inates in Southern and Eastern Europe, Latin America, and
Asia.4e6 HCV genotypes 2 and 3 are common in Latin Amer-
ica, Europe, and Asia, with rates varying by country.6e8
HCV genotypes 2 and 3 represent 16% and 12%, respectively,
of HCV infections in the United States.9,10
Historically, therapies for HCV genotype 1, 2, and 3
infection have been peginterferon (pegIFN)-based. PegIFN
is associated with adverse events including influenza-like
symptoms and depression. Many patients decline pegIFN
therapy, and a substantial number of patients with HCV
infection have contraindications for pegIFN-based therapy
due to co-existing medical conditions.
The former standard of care for treatment of HCV
genotype 1 infection was pegIFN and ribavirin (RBV) with
either telaprevir or boceprevir administered for up to 48
weeks, which resulted in sustained virologic response (SVR)
rates of 66%e75% in treatment-na€ıve patients.11,12 The cur-
rent standard of care is 12 weeks of the NS5B polymerase in-
hibitor sofosbuvir administeredwith pegIFN/RBVor 12weeks
of the protease inhibitor simeprevir with 24weeks of pegIFN/
RBV. These therapies achieve SVR rates of 80%e90%.13,14
Recent phase 3 trials have shown encouraging results for
pegIFN-free regimens in genotype 1-infected patients.15e21
For genotype 2- or 3-infected patients, pegIFN/RBV for
up to 24 weeks was formerly the standard of care. This
resulted in SVR rates of 54%e78% in treatment-na€ıve
genotype 2-infected patients and 64%e66% in treatment-
na€ıve genotype 3-infected patients.22e24 An SVR rate of 93%
has been reported among genotype 2-infected patients
receiving 12 weeks of sofosbuvir plus RBV, and an SVR
rate of 85% has been reported among genotype 3-infected
patients receiving 24 weeks of sofosbuvir plus RBV.25
Ombitasvir (ABT-267) is an HCV NS5A inhibitor dosed once
daily.26,27 ABT-450 is an HCVNS3/4A protease inhibitor, iden-
tified by AbbVie and Enanta as a lead compound for clinical
development. ABT-450 is co-dosed with low-dose ritonavir,
a CYP3A4 inhibitor, to achieve therapeutic exposures at
lowerdoses andat oncedaily dosing frequency (the combina-
tion is denoted ABT-450/r).27 Ombitasvir has picomolar
potency and ABT-450 has nanomolar potency against HCVdemonstrated high SVR rates and tolerability of combination
regimens that include ABT-450/r and ombitasvir with or
without ribavirin in genotype 1-infected
patients.17,18,21,28e31 In this exploratoryphase2 study,weas-
sessed the safety andefficacy of pegIFN-free regimens of om-
bitasvir and ABT-450/r with or without RBV in treatment-
na€ıve adults with chronic HCV genotype 1, 2, or 3 infection.
Patients and methods
Study design and participants
This was an open-label, sequential arm, multicenter, com-
bination treatment phase 2 study. Patients were screened
and enrolled at 15 sites in the United States from September
2011 to March 2012. Treatment-na€ıve adults age 18e65 years
(inclusive) with a BMI 18 and <35 kg/m2 and general good
health, who were chronically infected with HCV genotype
1, 2, or 3 without evidence of cirrhosis, were eligible.
Absence of cirrhosis was based on documented results of a Fi-
broTest score of 0.72 and Aspartate Aminotransferase to
Platelet Ratio 2, or Fibroscan result of <9.6 kPa at
screening, or a liver biopsywithin the last 36months. Cohorts
enrolling HCV genotype 1-infected patients were required to
include at least 5 patientswithHCV subgenotype 1a infection
and at least 2 patients with HCV subgenotype 1b infection.
Cohorts enrolling HCV genotype 2-infected patients were
required to include at least 2 patients with HCV subgenotype
2a infection and at least 5 patients with HCV subgenotype 2b
infection. Patientswere excluded if they had HIV or hepatitis
B co-infection, or if they previously used any investigational
or commercially available anti-HCV agents.
The study was performed in accordance with Good
Clinical Practice guidelines and the Declaration of Helsinki,
and was approved by the relevant institutional review
boards and regulatory agencies. All patients provided writ-
ten informed consent.
Procedures
Eligible patients received either ombitasvir and ABT-450/r
with RBV (Arm 1) or ombitasvir and ABT-450/r without RBV
(Arm 2) for 12 weeks. Each arm included a cohort of
genotype 1-infected patients, a cohort of genotype 2-
infected patients, and a cohort of genotype 3-infected
patients. Arms were enrolled sequentially. Once a cohort
within Arm 1 was fully enrolled, the cohort of the same
genotype in Arm 2 began enrolling patients. Patients
received ombitasvir 25 mg once daily and ABT-450/r
200/100 mg once daily. RBV dosing was weight-based
(1000 mg or 1200 mg total daily divided into 2 daily doses).
Ombitasvir and ABT-450/r  ribavirin for HCV genotype 1e3 199HCV genotype and subgenotype were assessed from
screening-visit blood samples using the Versant HCV Geno-
type Inno-LiPA Assay, version 2.0 or higher (LiPA; Siemens
Healthcare Diagnostics, Tarrytown, NY). Because of the
known limitations with this assay’s ability to determine sub-
genotypes for genotypes 2 and 3, an additional analysis was
conducted on some samples from genotypes 2 and 3 in-
fected patients. The NS3 and NS5A genes were amplified
by reverse transcription-PCR (RT-PCR) from viral RNA using
subgenotype-specific primers. These PCR products were
sequenced by a third party vendor, and the genotypes of
the resulting nucleotide sequences were determined by
Basic Local Alignment Search Tool analysis against se-
quences in GenBank. In addition, the NS5A gene amplified
from baseline samples from all genotype 2- and 3-
infected patients was used to perform a phylogenetic anal-
ysis (maximum-likelihood tree with 100 bootstrapping repli-
cates) in order to confirm the subgenotype of virus in each
sample.
Blood samples for assessing plasma HCV RNA levels were
collected at the screening-visit, prior to dosing on study day
1, day 3, weekly through week 12, and at post-treatment
weeks 2, 4, 8, 12, 24, 36, and 48, or upon patient
discontinuation. A central laboratory assessed plasma HCV
RNA levels for each sample collected using the Roche
COBAS TaqMan real-time reverse transcriptase-PCR (RT-
PCR) assay, which has a lower limit of detection (LLOD) of
15 IU/mL and a lower limit of quantitation (LLOQ) of
25 IU/mL.
Virologic stopping criteria were: (a) failure to achieve 2
log10 IU/mL HCV RNA decrease at week 1; (b) confirmed in-
crease from nadir in HCV RNA >1 log10 IU/mL at any time
point; (c) failure to achieve HCV RNA < LLOQ at week 6;
or (d) confirmed HCV RNA > LLOQ (defined as 2 consecutive
HCV RNA measurements > LLOQ) at any point after HCV
RNA < LLOQ. Virologic breakthrough during treatment
was defined as confirmed increase of at least
1 log10 IU/mL above nadir or confirmed HCV RNA > LLOQ
for patients who previously achieved HCV RNA < LLOQ dur-
ing treatment. Relapse was defined as confirmed HCV
RNA > LLOQ post-treatment for patients with HCV
RNA < LLOQ at the end of treatment.
For resistance-associated variant testing, viral RNA was
extracted from plasma samples collected at baseline and
after treatment failure. The target gene was amplified from
HCV viral RNA by RT-PCR using subgenotype-specific
primers for NS3/4A or NS5A. The PCR product was used as
the template for DNA sequencing which was performed by a
third party, Good Laboratory Practice (GLP)-certified labo-
ratory. In addition, the NS5A PCR product or a secondary
PCR product containing the protease catalytic domain
generated from the larger NS3/4A RT-PCR product was
inserted into a DNA plasmid vector, transformed into an Es-
cherichia coli host, and plasmid DNA from individual bacte-
rial clones was purified. The inserted NS3 protease or NS5A
gene was sequenced from 47 to 97 clones per sample
(average Z 82).
Safety and tolerability assessment occurred at all study
visits and included physical examinations, clinical labora-
tory tests, twelve-lead electrocardiography, and vital signs.
Number and percentage of patients reporting treatment-
emergent adverse events were tabulated by MedicalDictionary for Regulatory Activities (MedDRA) System Organ
Class and preferred term. Tabulations of treatment-
emergent adverse events were also provided by severity
rating and relationship to study drug. All adverse events
reported from the time of study drug administration until
30 days following discontinuation of study drug administra-
tion were collected. Serious adverse events were collected
from the time the patients signed the informed consent
through the 48-week post-treatment period.
Statistical analysis
The primary endpoint in this exploratory study was the
percentage of patients with HCV RNA suppressed below
LLOQ from week 4 through week 12. Secondary endpoints
included percentage of patients with sustained virologic
response (HCV RNA < LLOQ) at 12 weeks post-treatment
(SVR12) and percentage of patients with sustained virologic
response at 24 weeks post-treatment (SVR24). Demo-
graphic, safety, and efficacy analyses were performed on
all patients who received at least one dose of study drug.
All statistical tests and confidence intervals were 2-sided
with an a level of 0.05. SAS for the UNIX operating system
was used for all analyses. For analysis of adverse events,
Arms 1 and 2 were compared using Fisher’s exact test.
This study is registered with ClinicalTrials.gov, number
NCT01458535.
Results
One hundred forty patients were screened and 61 patients
were enrolled in the study. Commonly occurring reasons for
exclusion included: (a) an abnormal laboratory result at
screening, (b) an exclusionary FibroTest score or Aspartate
Aminotransferase to Platelet Ratio, and (c) the appropriate
cohort for the study patient was already fully enrolled. All
enrolled patients received at least 1 dose of study drug
(Fig. 1). Baseline characteristics were generally well-
balanced between cohorts of the same genotype
(Table 1). Phylogenetic analysis indicated that the HCV sub-
genotype designation for all patients was accurate
(Supplemental Fig. 1).
Efficacy
On-treatment and post-treatment virology results for each
individual patient are shown in Supplemental Fig. 2. Viro-
logic response rates are presented in Table 2. Among pa-
tients in Arm 1 (ombitasvir and ABT-450/r with RBV) HCV
RNA was suppressed below LLOQ from week 4 through 12
in 10 (100%; 95% CI, 69e100) HCV genotype 1-infected pa-
tients, 9 (90%; 95% CI, 56e100) HCV genotype 2-infected
patients, and 7 (70%; 95% CI, 35e93) HCV genotype 3-
infected patients. Among patients in Arm 2 (ombitasvir
and ABT-450/r without RBV) HCV RNA was suppressed below
LLOQ from week 4 through 12 in 9 (90%; 95% CI, 56e100)
HCV genotype 1-infected patients, 8 (80%; 95% CI, 44e97)
HCV genotype 2-infected patients, and 2 (18%; 95% CI,
2e52) HCV genotype 3-infected patients. The rate of HCV
RNA suppression below LLOQ from week 4 through 12 was
greater with the RBV-containing regimen than the
Figure 1 Study profile. Thirty patients with HCV genotype 1-3 received at least one dose of ombitasvir and ABT-450/r with riba-
virin. Thirty-one patients with HCV genotype 1e3 received at least one dose of ombitasvir and ABT-450/r without ribavirin.
200 E. Lawitz et al.RBV-free regimen overall (Arm 1 vs. Arm 2, PZ 0.037) and
in HCV genotype 3-infected patients (Cohort 3 vs. Cohort 6,
P Z 0.037) (Table 3).
SVR12 was achieved by 10 (100%; 95% CI 69e100) HCV ge-
notype 1-infected patients, 8 (80%; 95% CI, 44e97) HCV ge-
notype 2-infected patients, and 5 (50%; 95% CI, 19e81) HCV
genotype 3-infected patients receiving the RBV-containing
regimen. All of these patients went on to achieve SVR24,
except for 1 HCV genotype 3-infected patient who relapsed
at post-treatment week 24. Phylogenetic analysis indicatesTable 1 Baseline demographics and disease characteristics.
Arm 1: Ombitasvir þ ABT-450/r þ RB
Cohort 1: GT1
N Z 10
Cohort 2: GT2
N Z 10
Coh
N Z
Male Gender 2 (20) 8 (80) 7 (7
White Race 10 (100) 9 (90) 10 (
Hispanic/Latino 0 2 (20) 5 (5
Age (years) 44.3 (12.19) 51.1 (8.25) 40.3
Body-mass index (kg/m2) 25.9 (3.56) 27.9 (3.79) 29.5
IL28 Genotype CC 1 (10) 2 (20) 2 (2
HCV Subgenotype
a 8 (80) 2 (20) 10 (
b 2 (20) 8 (80) 0
HCV RNA (log10 IU/mL) 6.53 (0.62) 6.65 (0.46) 5.80
Fibrosis scorea
F0eF1, n/N (%)
6/7 (86) 8/10 (80) 6/9
Baseline resistance-associated variants
NS3 0 0 1 (1
NS5A 0 0 0
Data are N (%) or mean (SD), unless otherwise indicated.
a Fibrosis score was not available for all patients.that this was likely a new infection with HCV subgenotype
2b. The resulting SVR24 rate was 40% (95% CI, 12e74) in
HCV genotype 3-infected patients receiving the RBV-
containing regimen. SVR12 was achieved by 6 (60%; 95%
CI, 26e88) HCV genotype 1-infected patients, 6 (60%; 95%
CI, 26e88) HCV genotype 2-infected patients, and 1 (9%;
95% CI, 0e41) HCV genotype 3-infected patient receiving
the RBV-free regimen. All of these patients achieved
SVR24. SVR12 rates were greater with the RBV-containing
regimen compared to the RBV-free regimen overall (Arm 1V Arm 2: Ombitasvir þ ABT-450/r
ort 3: GT3
10
Cohort 4: GT1
N Z 10
Cohort 5: GT2
N Z 10
Cohort 6: GT3
N Z 11
0) 3 (30) 7 (70) 7 (64)
100) 9 (90) 10 (100) 11 (100)
0) 2 (20) 1 (10) 3 (27)
(13.10) 45.9 (7.03) 54.9 (10.85) 48.7 (8.91)
(4.03) 27.4 (4.13) 27.2 (3.57) 27.1 (5.23)
0) 4 (40) 4 (40) 3 (27)
100) 8 (80) 2 (20) 11 (100)
2 (20) 8 (80) 0
(0.76) 6.39 (0.55) 6.46 (0.78) 6.33 (0.66)
(67) 5/7 (71) 6/7 (86) 5/8 (63)
0) 0 0 1 (9)
3 (30) 1 (10) 0
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Ombitasvir and ABT-450/r  ribavirin for HCV genotype 1e3 201vs. Arm 2, PZ 0.005), in HCV genotype 1-infected patients
(Cohort 1 vs. Cohort 4, PZ 0.037), and in HCV genotype 3-
infected patients (Cohort 3 vs. Cohort 6, P Z 0.046)
(Table 3). SVR24 rates with the RBV-containing regimen
compared to the RBV-free regimen were greater overall
(Arm 1 vs. Arm 2, P Z 0.008) and in HCV genotype 1-
infected patients (Cohort 1 vs. Cohort 4, P Z 0.037).
Among patients receiving the RBV-containing regimen,
no HCV genotype 1-infected patient experienced virologic
failure, 1 HCV genotype 2-infected patient experienced
breakthrough, and there were 3 breakthroughs and 2
relapses in HCV genotype 3-infected patients. Among
patients receiving the RBV-free regimen, there was 1
breakthrough and 2 relapses in a genotype 1-infected
patient, and 1 breakthrough and 2 relapses in genotype 2-
infected patients; there were 8 breakthroughs and 1
relapse in genotype 3-infected patients. All three HCV
genotype 1-infected patients experiencing virologic failure
had subgenotype 1a. All four HCV genotype 2-infected
patients experiencing virologic failure had subgenotype
2b. Two patients who relapsed (1 HCV genotype 2-
infected patient and 1 HCV genotype 3-infected patient
receiving the RBV-free regimen) took less than 40% of their
prescribed doses of each study drug.
Of the 4 patients with baseline resistance-associated
variants in NS5A, 1 subgenotype 1a-infected patient and 1
subgenotype 2a-infected patient achieved SVR12 and SVR24,
1 subgenotype 1a-infected patient experienced break-
through, and 1 subgenotype 1a-infected patient relapsed.
Two subgenotype 3a-infected patients had baseline
resistance-associated variants in NS3 protease; both experi-
enced breakthrough. The 4 patients with a baseline
resistance-associated variant who experienced virologic
failure had 2-class resistance at the time of failure. Addi-
tional data on resistance-associated variants at baseline
and at time of virologic failure are in the Supplemental
Table.
Safety
The most common treatment-emergent adverse events
were fatigue, nausea, and headache (Table 4). The major-
ity of treatment-emergent adverse events were mild or
moderate. Three patients had treatment-emergent serious
adverse events (meningitis herpes; arteriosclerosis; and
road traffic accident, with traumatic liver injury, facial
bones fracture, rib fracture, and lumbar vertebral frac-
ture). Each of these events was deemed not related to
study drug by the investigators. One serious adverse event
(meningitis herpes) led to discontinuation of study drug.
This was the only discontinuation due to an adverse event.
The patient with the serious adverse event of arterioscle-
rosis died 8 days post-treatment. Autopsy revealed myocar-
dial hypertrophy, arteriolonephrosclerosis and cardiac
arteriosclerosis, hyalination/mineralization of central arte-
rioles, left anterior descending coronary artery stenosis,
and myocardial fibrosis. This event was considered not
related to study drugs by the investigator.
Treatment-emergent grade 3e4 laboratory abnormalities
were infrequent (Table 5). One patient had a grade 4 ALT
elevation concurrent with a grade 3 AST elevation. These el-
evations coincidedwith use of hormonal contraceptives. One
Table 3 Comparison of response rates in patients receiving the RBV-containing vs. RBV-free regimen.
Difference (95% CI) P value
HCV RNA< LLOQ from week 4 through week 12
GT1: Cohort 1 vs. Cohort 4 16.33 (23.14, 55.79) 0.157
GT2: Cohort 2 vs. Cohort 5 10.49 (26.22, 47.20) 0.999
GT3: Cohort 3 vs. Cohort 6 45.76 (7.99, 83.54) 0.045)
Arm 1 vs. Arm 2 24.82 (2.90, 46.74) 0.037)
SVR12
GT1: Cohort 1 vs. Cohort 4 38.78 (1.70, 79.25) 0.037)
GT2: Cohort 2 vs. Cohort 5 19.51 (30.93, 69.95) 0.394
GT3: Cohort 3 vs. Cohort 6 40.68 (0.06, 81.42) 0.046)
Arm 1 vs. Arm 2 33.46 (8.12, 58.80) 0.005))
SVR24
GT1: Cohort 1 vs. Cohort 4 38.78 (1.70, 79.25) 0.037)
GT2: Cohort 2 vs. Cohort 5 28.83 (24.70, 82.36) 0.232
GT3: Cohort 3 vs. Cohort 6 27.97 (12.77, 68.71) 0.148
Arm 1 vs. Arm 2 31.69 (5.98, 57.41) 0.008))
Patients in Arm 1 (Cohort 1, Cohort 2, and Cohort 3) received ombitasvir þ ABT-450/r þ RBV.
Patients in Arm 2 (Cohort 4, Cohort 5, and Cohort 6) received ombitasvir þ ABT-450/r.
Comparison was performed by strata-adjusted CMH.
),))Statistically significant at the 0.05 and 0.01 level, respectively.
202 E. Lawitz et al.patient had a grade 3 elevation in ALTwithout a concomitant
grade 3e4 elevation in AST; this patient subsequently discon-
tinued prematurely due to virologic failure. In both patients,
these elevationswere asymptomatic and neither patient had
a concomitant grade 3e4 elevation in total bilirubin. Four of
the nine grade 3e4 laboratory abnormalities occurred at a
single visit. The one documented grade 3 elevation of bili-
rubin was mainly indirect. There were no grade 3e4 reduc-
tions in hemoglobin, and no patient received a transfusion.
All grade 3e4 laboratory abnormalities resolved on treat-
ment or shortly thereafter. There were no discontinuations
due to laboratory abnormalities.
Discussion
In this exploratory study of pegIFN-free regimens of
ombitasvir and ABT-450/r with or without RBV in treat-
ment-na€ıve, non-cirrhotic patients with HCV genotype 1, 2,
or 3 infection, rapid suppression of HCV RNA was observed
in the majority of patients receiving the RBV-containing
regimen, regardless of patient genotype. Among patientsTable 4 Treatment-emergent adverse events.
Arm 1: Ombitasvir þ ABT-45
N Z 30
Any adverse event 26 (87)
Common adverse events
Fatigue 11 (37)
Nausea 10 (33)
Headache 7 (23)
Diarrhea 4 (13)
Arthralgia 4 (13)
Cough 4 (13)
Depression 4 (13)
Data are N (%). Events occurring in more than 10% of patients in eithe
for depression. P values for all other comparisons between treatmenreceiving the RBV-free regimen, most HCV genotype 1- and
2-infected patients demonstrated HCV RNA suppressed
below LLOQ from week 4 through 12; however, few patients
with HCV genotype 3 infection achieved this endpoint. The
RBV-containing regimen resulted in high SVR12 rates, while
the SVR12 rates observed in patients receiving the RBV-free
regimen were lower. All patients who achieved SVR12 in this
study went on to achieve SVR24, except 1 HCV genotype 3-
infected patient whose relapse was likely a new infection,
based on phylogenetic analysis.
In the current study, response rates were high in
patients with HCV genotype 1 infection who received either
the RBV-containing or the RBV-free regimen. It is important
to note that 80% of the HCV genotype 1-infected patients in
this study had subgenotype 1a, which has reportedly been
more difficult to treat than subgenotype 1b when using
protease inhibitor-based direct-acting antiviral regi-
mens.32e34 Combination regimens that include ombitasvir
and ABT-450/r with or without RBV have been studied in ge-
notype 1-infected patients in other phase 2 and phase 3
studies. In a phase 2b trial evaluating various combinations0/r þ RBV Arm 2: Ombitasvir þ ABT-450/r
N Z 31
28 (90)
8 (26)
5 (16)
4 (13)
5 (16)
3 (10)
2 (7)
0
r arm are listed. P value for comparisons between arms was 0.053
t groups were >0.1.
Table 5 Treatment-emergent grade 3/4 laboratory abnormalities.
Arm 1: Ombitasvir þ ABT-450/r þ RBV
N Z 30
Arm 2: Ombitasvir þ ABT-450/r
N Z 31
Grade 3 event
ALT >5-20X ULN 0 1 (3)
AST >5-20X ULN 1 (3) 0
Bilirubin >3-10X ULN 1 (3) 0
Uric Acid 12.1e15.0 mg/dL 0 0
Inorganic Phosphate <0.6e0.3 mmol/L 1 (3) 0
Glucose > 250e500 mg/dL 0 1 (3)
Triglycerides >500e1000 mg/dL 1 (3) 1 (3)
Hemoglobin <8.0e6.5 g/dL 0 0
Grade 4 event
ALT >20X ULN 1 (3) 0
AST >20X ULN 0 0
Bilirubin >10X ULN 0 0
Uric Acid >15.0 mg/dL 1 (3) 0
Inorganic phosphate <0.3 mmol/L 0 0
Glucose >500 mg/dL 0 0
Triglycerides >1000 mg/dL 0 0
Hemoglobin <6.5 g/dL 0 0
Data are N (%).
Ombitasvir and ABT-450/r  ribavirin for HCV genotype 1e3 203of ombitasvir, ABT-450/r, the nonnucleoside polymerase in-
hibitor dasabuvir, and RBV administered for 8, 12, or 24
weeks in genotype 1-infected patients, SVR24 rates up to
96.2% in treatment-na€ıve patients and 95.3% in prior
pegIFN/RBV-null responder patients were observed.29 A
phase 2 study assessing a 12-week regimen of ABT-450/r
and ombitasvir without RBV in genotype 1b-infected pa-
tients reported SVR12 rates of 95.2% in treatment-na€ıve pa-
tients and 90.0% in prior pegIFN/RBV-null responder
patients.30 In phase 3 trials, a regimen of ombitasvir/ABT-
450/r and dasabuvir with RBV was evaluated in treat-
ment-na€ıve and pegIFN/RBV treatment-experienced HCV
genotype 1-infected patients with and without cirrhosis.
Regimens of ombitasvir/ABT-450/r and dasabuvir with RBV
achieved SVR12 rates up to 96% in each of the large patient
populations evaluated in these trials.17,21,31 Other phase 3
trials evaluated this regimen with and without RBV.18
SVR12 rates of 97.0% and 90.2% were observed in HCV subge-
notype 1a-infected patients receiving ombitasvir/ABT-450/
r and dasabuvir with and without RBV, respectively.18 SVR12
rates in HCV subgenotype 1b-infected patients receiving
ombitasvir/ABT-450/r and dasabuvir with and without RBV
were 99.0% and 99.5%, respectively.18
Response rates in this study in HCV genotype 2-infected
patients were high despite 80% of the patients having
subgenotype 2b infection, which has been identified as
more difficult to treat with pegIFN-containing regimens
than subgenotype 2a.22,35,36 The exploratory regimens in
this study resulted in SVR in some HCV genotype 3-
infected patients, but the overall SVR rates in this group
of patients were low.
The results of this study also indicate that the safety and
tolerability of both the RBV-containing and RBV-free
regimen compare favorably to pegIFN-based therapy. Pa-
tients receiving these all-oral regimens avoid the subcu-
taneous injections required for pegIFN therapy. Also, the
rates of adverse events commonly associated with pegIFNtreatment, such as fatigue, headache, nausea, and depres-
sion, were lower in patients in this study than previously
reported in patients receiving pegIFN.37 One patient in this
study had a grade 3 bilirubin elevation; this elevation was
predominantly indirect bilirubin, consistent with the known
effect of protease inhibitors on the organic anion-
transporting polypeptide 1B1.38,39 Overall, the regimens
under investigation were generally well-tolerated by pa-
tients in this study. Many patients who have contraindica-
tions for pegIFN therapy due to comorbidities may be
eligible for this pegIFN-free therapy.
This study is limited by the small sample size for each of
the 3 genotypes under investigation. The small size limits the
ability to determine the impact of baseline characteristics on
response. In addition, patientswith cirrhosis,whohave lower
response rates to pegIFN/RBV therapy, were not included in
this study.40 Arms were enrolled sequentially in this small
exploratory study. This design may result in some imbalance
in baseline and disease characteristics between arms.
In summary, this exploratory study characterized the
safety and antiviral activity of ombitasvir and ABT-450/r
with or without RBV in patients with HCV genotypes 1, 2, or 3
infection. The regimens were generally well-tolerated and
SVR was achieved in most patients with HCV genotype 1 or 2
infection, but low SVR rates were observed in HCV genotype
3-infected patients. While regimens including an additional
direct-acting antiviral agentmay be needed tomaximize SVR
rates across patient populations with negative predictors of
response, the results of this study support the continued
exploration of this 2 direct-acting antiviral regimen.Acknowledgments
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